EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q4 EPS of ($0.33), $0.16 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $14.03 million versus the consensus estimate of $8.88 million.

Financial Outlook

We expect that our cash, cash equivalents, and investments on December 31, 2023, will enable us to fund operations through topline data for the planned Phase 3 clinical trials of EYP-1901 for wet AMD in 2026.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.